Global Cancer Nanotherapy Market – Industry Trends and Forecast to 2029

Market Analysis and Insights

Cancer nanotherapy is nanocarriers-based drugs that are widely used for the treatment of various kind cancers. The application of nanotechnology in drugs has enhanced the efficacy and changes the treatment landscape for patients suffering from cancer.

• The cancer nanotherapy is used to cure cancer patient. Data Bridge Market Research analyses that the cancer nanotherapy market will grow at a CAGR of 11.20% during the forecast period of 2022 to 2029. “Hospitals” of end users segment is dominating the market owing to the rising number of hospital facilities in the developing and developed eocnomies.

Cancer Nanotherapy Market Dynamics

Drivers

• Increasing number of patients suffering from cancer

The rise in the number of people with cancer is increasing on daily basis and the detection of cancer is also a very difficult and it act as a major driver that will result in the expansion of the growth rate of the treatment market.

• Ongoing clinical trials are being conducted by many pharmaceuticals companies

Another significant factor influencing the growth rate of cancer nanotherapy market is the pharmaceuticals companies regularly working to make the drug more and more efficient investors are investing very hefty money to cure these diseases.

Opportunities

Surge volume of patients suffering from cancer and development in newer diagnostics devices, advances in nanotechnology to medicine drugs, special designation from the regulatory authority that motivates the companies to invest further will result in the expansion of cancer nanotherapy market. 

Restraints/Challenges

However, lack of regulatory standards in the examination of nano therapy and also the high cost of the treatment will impede the growth rate of cancer nanotherapy market. The side effects of antibiotics and self-medication will further challenge the market in the forecast period mentioned above.

This cancer nanotherapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on cancer nanotherapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to the international federation of Alzheimer's associations, Alzheimer's Disease International, more than 50 million people are suffering from dementia globally, and is projected to double every 20 years, which will reach 80 million by 2030 and 152 million by 2050.

In 2020, the total cancer burden in the world increased to 19.3 million new cases and is predicted to rise to 28.4 million new cancer cases in 2040. This increasing burden of chronic diseases is expected to propel the demand for effective therapeutics treatment based on nanomedicine, thus driving the market.

Cancer nanotherapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cancer Nanotherapy Market

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the research and development pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Recent Development

• For instance, in 2020, a research team from The Department of Chemical Sciences, University of Padua investigated and confirmed the effectiveness of inorganic 4D nanoparticles in the biomedical field. 4D nanomedicine offers several advantages to the biomedical field including reduced side effects in a living organism, minimal environmental impact, improved quality of care, and spontaneous effect.

Global Cancer Nanotherapy Market Scope

The cancer nanotherapy market is segmented on the basis of indication, drug, carrier, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Renal cancer
• HIV-associated Kaposi’s sarcoma
• Ovarian cancer
• Breast cancer
• Multiple myeloma
• Non-small-cell lung cancer
• Others

On the basis of indication, the cancer nanotherapy market is segmented into renal cancer, HIV-associated Kaposi’s sarcoma, ovarian cancer, breast cancer, multiple myeloma, non-small-cell lung cancer and others.

Drug carrier

• Doxorubicin
• Daunorubicin
• Paclitaxel
• l-asparaginase
• Vincristine
• Others

The drug segment for cancer nanotherapy market includes doxorubicin, daunorubicin, paclitaxel, l-asparaginase, vincristine and others.

Carrier

• Polymer based nanocarriers
• Lipid based nanocarriers
• Others

On the basis of carrier, cancer nanotherapy market is segmented into polymer based nanocarriers, lipid based nanocarriers and others

Route of Administration

• Intravenous
• Intramuscular
• Others

Route of administration segment of cancer nanotherapy market is segmented into intravenous, intramuscular and others.

End Use

• Specialty Clinic
• Hospital
• Others

On the basis of end-user, the cancer nanotherapy market is segmented into hospitals, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cancer nanotherapy market has also been segmented based on the distribution channel into hospital pharmacy, online pharmacy, retail pharmacy others.

Pipeline Analysis

Several biologic drugs have been recently approved, revolutionizing ABC treatment algorithms: key examples are CDK4/6-inhibitors and the PI3K-inhibitor alpelisib for endocrine-positive ABC; atezolizumab for triple-negative cancers; two PARP-inhibitors for HER2-negative germinal BRCA-mutated cancers. Additionally, multiple drugs are demonstrating activity in late-phase clinical trials for all subtypes. While some of these represent pharmacological evolutions of previously approved drugs, some others might pave the way for new paradigms in ABC, challenging both its classification and current treatment algorithms.

Cancer Nanotherapy Market Regional Analysis/Insights

The cancer nanotherapy market is analysed and market size insights and trends are provided by country, indication, drug, carrier, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cancer nanotherapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cancer nanotherapy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to high prevalence cases of cancer and number of FDA approval drugs in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the focus of various global companies to expand their presence in this particular region in this particular region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Cancer Nanotherapy Market Share Analysis

The cancer nanotherapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer nanotherapy market.

Some of the major players operating in the cancer nanotherapy market are Celgene Corporation, Abbott, Agilent Technologies, Inc., BD, bioMérieux SA, NeoGenomics Laboratories, Inc., Telerad Tech, F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC COMPANY, Galen Limited, Pacira BioSciences, Inc, Johnson & Johnson Services, Inc, Samyang Biopharmaceuticals Corporation, Spectrum Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, MagForce AG, Merrimack among others.

SKU-52040